These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28141765)

  • 21. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
    Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
    Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
    Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT
    J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
    VanderVeen DK; Cataltepe SU
    Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
    Baumal CR; Goldberg RA; Fein JG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
    Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
    JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants.
    Kaempfen S; Neumann RP; Jost K; Schulzke SM
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011893. PubMed ID: 29499081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
    Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
    JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity.
    Belenje A; Reddy RU; Parmeswarappa DC; Padhi TR; Subbarao B; Jalali S
    Eye (Lond); 2024 Apr; 38(6):1097-1103. PubMed ID: 37968517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
    Klufas MA; Chan RV
    J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
    Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
    Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity.
    Minturn R; Hartigan K; Vegunta S; Boente C; Golzarri-Arroyo L; Hynes E; Laughlin E; Haider K; Kua KL
    BMC Ophthalmol; 2024 May; 24(1):220. PubMed ID: 38790043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.